Pliant Therapeutics, Inc. - PLRX Net earnings per one share for the last twelve months

This price trend reflects the EPS TTM dynamics for Pliant Therapeutics (PLRX), which currently stands at 49.10. Pliant Therapeutics (PLRX) generates revenue by developing small molecules to combat organ fibrosis, focusing on insurance reimbursements. High R&D costs and patent protection create significant barriers to entry for competitors under strict FDA oversight. Liquidity supports financial stability, although business success depends on the results of final drug trials.
Pliant Therapeutics, Inc. - analytical breakdowns and key metrics (PLRX)

Strategic alliances formed by Pliant Therapeutics (PLRX) in the fight against fibrosis determine the company's financial stability through capital inflows from pharma behemoths. By analyzing the YoY TTM net income growth per share, an investor can observe the percentage change in EPS over the last four quarters, allowing for an assessment of molecule commercialization efficiency and a balancing of the risk of overpaying for assets relative to profit potential.